Influence of high dose inhaled steroids on hypothalamo-pituitary-adrenal axis function in Japanese patients with asthma: A comparison over the course of time

Internal Medicine

Volumn 35, Issue 5, 1996, Pages 362-366

  Hasegawa, Tsuyoshi ^a   Ishihara, Kyosuke ^a   Fujii, Hiroshi ^a   Hajiro, Takashi ^a   Watanabe, Isao ^a   Nishimura, Takashi ^a   Okazaki, Miki ^a   Katakami, Nobuyuki ^a   Umeda, Bun Ichi ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

adrenal suppression; beclomethasone dipropionate (BDP); side effects

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; HYDROCORTISONE; TETRACOSACTIDE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; MALE;

EID: 0029900377     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.35.362     Document Type: Article

References (15)

1. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung, and Blood Institute. NIH Publication No. 95-3659, 1995.
2. Geddes DM. Inhaled corticosteroids: benefits and risks. Thorax 47: 404, 1992 (editorial) (see comments).
3. Barnes NC. Safety of high-dose inhaled corticosteroids. Respir Med 87 Suppl A: 27, 1993.
4. Smith MJ, Hodson ME. Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax 38:676, 1983.
5. Boe J, Bakke P, Rodolen T, Skovlund E, Gulsvik A. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society. Eur Respir J 7: 2179, 1994.
6. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamopituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med 85: 501, 1991.
7. Altman LC, Findlay SR, Lopez M, et al. Adrenal function in adult asthmatics during long-term daily treatment with 800, 1,200, and 1,600 μg triamcinolone acetonide. Multicenter study. Chest 101: 1250, 1992.
8. Brown PH, Greening AP, Crompton GK. Large volume spacer device and the influence of high dose beclomethasone dipropionate on hypothalamopituitary-adrenal axis function. Thorax 48: 233, 1993.
9. Fabbri L, Burge PS, Croonenborgh L, et al, and International Study Group. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 48: 817, 1993 (see comments).
10. Tornatore KM, Biocevich DM, Reed K, Tousley K, Singh JP, Venuto RC. Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation 59: 729, 1995.
11. Hasegawa T, Ishihara K, Matsumoto H, et al. Treatment modalities and hypothalamo-pituitary-adrenal axis suppression in Japanese patients with asthma. Nippon Kyobu Shikkan Gakkai Zasshi 32: 757, 1994.
12. Holt PR, Lowndes DW, Smithies E, Dixon GT. The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis - which tests should be used? Clin Exp Allergy 20: 145, 1990.
13. Brown PH, Blundell G, Greening AP, Crompton GK. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med 85: 511, 1991.
14. Harrison BDW, Rees LH, Cayton RM, Nabarro JDN. Recovery of hypothalamo-pituitary-adrenal function in asthmatics whose oral steroids have been stopped or reduced. Clin Endocrinol (Oxf) 17: 109, 1982.
15. Barnes PJ. Inhaled glucocorticoids for asthma. New Engl J Med 332: 868, 1995.